Long-term antibody and immune memory response induced by pulmonary delivery of the influenza iscomatrix vaccine

Clinical and Vaccine Immunology

Volumn 19, Issue 1, 2012, Pages 79-83

  Vujanic, Ana ^a   Snibson, Kenneth J ^a   Wee, Janet L K ^a,c   Edwards, Stirling J ^b   Pearse, Martin J ^b   Scheerlinck, Jean Pierre Y ^a   Sutton, Philip ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSL LIMITED   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; EWE; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGICAL MEMORY; LUNG; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INHALATION; ANIMALS; ANTIBODIES, VIRAL; BLOOD; CHOLESTEROL; DRUG COMBINATIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNOLOGIC MEMORY; INFLUENZA VACCINES; LUNG; PHOSPHOLIPIDS; SAPONINS; SHEEP; TIME FACTORS; VACCINATION;

EID: 84855681897     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05265-11     Document Type: Article

References (16)

1. Belshe RB, et al. 2000. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181:1133-1137. (Pubitemid 30194502)
2. Clements ML, Betts RF, Tierney EL, Murphy BR. 1986. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24:157-160. (Pubitemid 16090261)
3. Cox J, et al. 1997. Development of an influenza-IscomTM vaccine, p 33-49. In Gregoriadis G. (ed), Vaccine design: the role of cytokine networks. Plenum Press, New York, NY.
4. Dolovich MB, Dhand R. 2011. Aerosol drug delivery: developments in device design and clinical use. Lancet 377:1032-1045.
5. Drane D, Gittleson C, Boyle J, Maraskovsky E. 2007. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev. Vaccines 6:761-772. (Pubitemid 47607851)
6. Ichinohe, T. 2010. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design. Expert Rev. Vaccines 9:1315-1324.
7. Kendal AP, Pereira MS, Skehel JJ. 1982. Concepts and procedures for laboratory-based influenza surveillance. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Atlanta, GA.
8. Maraskovsky E, et al. 2009. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol. Cell Biol. 87:371-376.
9. Menzel M, Muellinger B, Weber N, Haeussinger K, Ziegler-Heitbrock L. 2005. Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. Vaccine 23:5113-5119. (Pubitemid 41318160)
10. Nardelli-Haefliger D, et al. 2005. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23:3634-3641. (Pubitemid 40692408)
11. Rothberg MB, Haessler SD. 2010. Complications of seasonal and pandemic influenza. Crit. Care Med. 38:e91-e97.
12. Scheerlinck JP, Snibson KJ, Bowles VM, Sutton P. 2008. Biomedical applications of sheep models: from asthma to vaccines. Trends Biotechnol. 26:259-266.
13. Song K, et al. 2010. Genetic immunization in the lung induces potent local and systemic immune responses. Proc. Natl. Acad. Sci. U. S. A. 107:22213-22218.
14. Vujanic A, et al. 2010. Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens. Vaccine 28:2593-2597.
15. Wee JL, et al. 2008. Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. Mucosal Immunol. 1:489-496.
16. WHO. 2002. Influenza vaccines. Wkly. Epidemiol. Rec. 77:230-240.